Cargando…
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
BACKGROUND: Advanced melanoma is characterized by a pronounced resistance to therapy leading to a limited patient survival of ~6 - 9 months. Here, we report on a novel bifunctional therapeutic fusion protein, designated anti-MCSP:TRAIL, that is comprised of a melanoma-associated chondroitin sulfate...
Autores principales: | de Bruyn, Marco, Rybczynska, Anna A, Wei, Yunwei, Schwenkert, Michael, Fey, Georg H, Dierckx, Rudi AJO, van Waarde, Aren, Helfrich, Wijnand, Bremer, Edwin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000402/ https://www.ncbi.nlm.nih.gov/pubmed/21092273 http://dx.doi.org/10.1186/1476-4598-9-301 |
Ejemplares similares
-
Isolation of a neural chondroitin sulfate proteoglycan with neurite outgrowth promoting properties
Publicado: (1994) -
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms
por: Yang, Jianbo, et al.
Publicado: (2004) -
Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma
por: Grossauer, Anna, et al.
Publicado: (2023) -
Select neurotrophins promote oligodendrocyte progenitor cell process outgrowth in the presence of chondroitin sulfate proteoglycans
por: Siebert, Justin R., et al.
Publicado: (2021) -
Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF
por: Uranowska, Karolina, et al.
Publicado: (2021)